NCT04155918View on ClinicalTrials.gov

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

September 3, 2020

Study Completion Date

September 3, 2020

Conditions
Gout Patients
Interventions
DRUG

Group 1: AR882 Alone and in Combination with Febuxostat (FBX)

AR882 + Febuxostat, AR882 alone, Febuxostat alone

DRUG

Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)

AR882 + Allopurinol, AR882 alone, Allopurinol alone

Trial Locations (1)

Unknown

Christchurch Clinical Studies Trust, Ltd (CCST), Christchurch

Sponsors
All Listed Sponsors
lead

Arthrosi Therapeutics

INDUSTRY